Zhong Guangwei, Luo Yanhong, Xiang Lingli, Xie Yong, Xie Qiying, Li Yunhui, Zhang Cheng
Institute of Integrated Chinese Traditional and Western Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.
Zhongguo Zhong Yao Za Zhi. 2010 Mar;35(6):776-81. doi: 10.4268/cjcmm20100626.
To observe the therapeutic effect of calming the liver and restraining the Yang formula in treating patients with mild or moderate degree of essential hypertension (syndrome of hyperactivity of liver-Yang), and to explore its mechanism in lowering blood pressure.
The 348 patients with EH of stage I , II were randomly divided into two groups, the 174 patients in the treated group were treated with the calming the liver and restraining the Yang formula, and the 174 patients in the control group were treated with amlodipine. The treatment course for them all was 12 weeks. The related clincial symptoms score and quality of life score estimated before and after treatment at 4th week, 8th week and 12th week were observed. Before and after treatment, the ambulatory blood pressure (AMBP), heart rate, blood lipid, serum livels of high-sensitivity C-reactive protein (Hs-CRP), Angiotensin-II (Ang II) and calcitonin gene-related peptide (CGRP) were measured respectively in 40 patients of the treared group and 40 patients of the control group.
After treatment, the treatment in the treated group showed an effect better than that in the control group in terms of nigh-time blood pressure reducing rate (P < 0.05). The reducing blood pressure variability and total effective rate in the treated group were no significant than that in the control group. In respect of reducing symptomatic scores on dizzy, soreness and weakness of the waist and knees, disturbed and dry and bitter of mouth, ameliorating quality of life score, decreasing the levels of heart rate, total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol(HDL-C) in the treated group were showing marked improvement as compared with that in the control group (P < 0.05 or P < 0.1). The improvement in the level of Ang II , Hs-CRP and CGRP before treatment in two groups were more significant than that after treatment (P < 0.05). However There were no difference in after treatment between the treated group and the control group.
The calming the liver and restraining the Yang formula shows favorable efficacy in lowering blood pressure on the patients with mild or moderate degree of essential hypertension. It can reduce the clincial symptoms, improve the quality of life, regulate blood lipid metabolism. Its mechanism may be related to the functional relieving inflammatory reaction and inhibition the activity of renin-angiotensin-aldosterone system (RAAS).
观察平肝潜阳方治疗轻、中度原发性高血压（肝阳上亢证）的疗效，并探讨其降压机制。
将348例Ⅰ、Ⅱ期原发性高血压患者随机分为两组，治疗组174例给予平肝潜阳方治疗，对照组174例给予氨氯地平治疗。两组疗程均为12周。观察第4周、8周、12周治疗前后的相关临床症状评分及生活质量评分。分别测定治疗组和对照组40例患者治疗前后的动态血压（AMBP）、心率、血脂、高敏C反应蛋白（Hs-CRP）、血管紧张素Ⅱ（AngⅡ）及降钙素基因相关肽（CGRP）水平。
治疗后，治疗组夜间血压下降率优于对照组（P<0.05）。治疗组血压变异性降低及总有效率与对照组比较差异无统计学意义。治疗组在改善头晕、腰膝酸软、口苦咽干等症状评分、提高生活质量评分、降低心率、总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）水平方面较对照组有明显改善（P<0.05或P<0.1）。两组治疗前AngⅡ、Hs-CRP及CGRP水平改善较治疗后更显著（P<0.05）。但治疗后治疗组与对照组比较差异无统计学意义。
平肝潜阳方治疗轻、中度原发性高血压患者降压疗效良好，能减轻临床症状，提高生活质量，调节血脂代谢。其机制可能与减轻炎症反应、抑制肾素-血管紧张素-醛固酮系统（RAAS）活性有关。
